The jury is still out on the genetics of pre-eclampsia

A Ugwumadu
St George’s, University of London, London, UK

Linked article: This is a mini commentary on KJ Gray et al. To view this article visit http://doi.org/10.1111/1471-0528.16441

The American obstetrician Joseph DeLee, ‘father of modern obstetrics’, founded the Chicago Lying-in Hospital in 1931 with his vision for women’s health, captured in a set of five stone plaques at the top of the cloister of the hospital’s building. Four of the five stone plaques are engraved with the names of pioneering clinicians whose contributions to the field of obstetrics and gynaecology have been seminal: Jan Palfyn (1650–1730), for introducing the obstetric forceps in the 1720s, Hendrik Van Deventer (1651–1724), for discovering obstetric anatomical disorders, William Smellie (1697–1763), for improving the design of the forceps, and Eduardo Porro (1842–1902), for introducing hysterectomy to stop postpartum haemorrhage. According to legend, the fifth stone plaque, in the centre, which is still blank today, is reserved for the physician/scientist who discovers the cause and cure of pre-eclampsia.

That clusters of pre-eclampsia occur in family units prompted the question whether pre-eclampsia is an inherited disorder, and if so, what is the mode of inheritance? Familial clustering opened the possibility of deploying genome-wide association studies (GWAS) for the identification of candidate genes and susceptibility loci for the development of pre-eclampsia and researchers have focused on this question since the discovery of DNA. However, till date, there has been no clearly defined causal association between a pre-eclampsia genotype and phenotype, except for heterozygous women who are pregnant with a long-chain hydroxyacyl-CoA dehydrogenase deficient-fetus, who have nearly 80% chance of developing HELLP syndrome or acute fatty liver of pregnancy. Defining the genetics and mode of inheritance of pre-eclampsia is challenged in part by the involvement of two genomes (maternal and fetal) and the wide spectrum of women who meet the diagnostic criteria according to the International Society for the Study of Hypertension in Pregnancy.

There is persuasive literature that coexisting maternal medical disorders such as diabetes, chronic hypertension, renal disease, autoimmune disease, antiphospholipid antibody syndrome and other maternal-fetal risk factors including obesity, dyslipidemia, nulliparity, previous/family history of pre-eclampsia, and multifetal gestation, increase the risk of pre-eclampsia. In this issue of the Journal, Gray et al. (BJOG 2020; http://doi.org/10.1111/1471-0528.16441) used single nucleotide polymorphisms (SNPs) for 21 distinct clinical traits for increased risk of pre-eclampsia within seven categories (cardiovascular, inflammatory/autoimmune, insulin resistance, liver, obesity, rena, and thrombophilia) from the European GWAS to test the hypothesis that women with genetic predisposition to these disorders would have increased risk of pre-eclampsia in a case/control sample of data from the largest known US pre-eclampsia GWAS. The authors’ findings that (i) risk alleles for raised diastolic blood pressure and increased body mass index were strongly associated with pre-eclampsia risk (more so for the early-onset disease variant), (ii) risk alleles for raised alkaline phosphatase levels, increased HDL, GFR and venous thromboembolism were protective, and (iii) no significant associations with the other traits examined, are consistent with the current status of pre-eclampsia and HELLP as highly complex disorders with variable clinical presentations depending on pre-pregnancy maternal conditions, fetal/placental genotypes, and maternal adaptation to the challenge of pregnancy.

So, pre-eclampsia is far from a Mendelian inherited type of genetic disease and the search for its cause and cure continues 90 years after DeLee’s vision!
Copyright © 2020 The Author. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd.